[go: up one dir, main page]

WO2000031538A1 - Essais en ecoulement lateral ameliores - Google Patents

Essais en ecoulement lateral ameliores Download PDF

Info

Publication number
WO2000031538A1
WO2000031538A1 PCT/US1999/027497 US9927497W WO0031538A1 WO 2000031538 A1 WO2000031538 A1 WO 2000031538A1 US 9927497 W US9927497 W US 9927497W WO 0031538 A1 WO0031538 A1 WO 0031538A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
control
agent
test strip
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/027497
Other languages
English (en)
Inventor
Alan J. Polito
Richard M. Thayer
Robert K. Dinello
George H. Sierra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PraxSys BioSystems Inc
Original Assignee
PraxSys BioSystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PraxSys BioSystems Inc filed Critical PraxSys BioSystems Inc
Priority to AU17390/00A priority Critical patent/AU1739000A/en
Publication of WO2000031538A1 publication Critical patent/WO2000031538A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated

Definitions

  • the invention relates to lateral flow assays, more particularly, the invention relates to improved lateral flows assays wherein an analyte binding agent is coupled to a detection agent and an analyte non-specific agent.
  • immunological testing methods which take advantage of the high specificity of the antigen-antibody reaction, provide one approach to measurement of analytes.
  • This document and all others cited to herein, are incorporated by reference as if reproduced fully below.
  • Such assays may also find use in various other applications, such as veterinary, food testing, or agricultural applications.
  • Immunoassays that provide a quantitative measurement of the amount of an analyte in a sample have previously used complex, multi-step procedures and expensive analyzers available only in a laboratory setting.
  • Immunochromatographic assays such as those described in GB 2,204,398A; U.S. Pat. Nos. 5,096,837, 5,238,652, and 5,266,497; Birnbaum, S. et al., Analytical Biochem. 206:168-171 (1992); Roberts, M. A. and R. A. Durst, Analytical Chem. 67:482-491 (1995); and Klimov, A. D. et al., Clinical Chem. 41:1360 (1995), are simpler, yet do not provide a quantitative measurement of an analyte. Instead, these immunochromatographic assays detect the presence (or absence) of an analyte above a defined cutoff level for the test performed. The lack of a quantitative measurement limits the usefulness of these assays.
  • the device comprises a sample addition port in fluid communication with at least one main channel.
  • the main channel comprises, in a direction of fluid flow, a main reagent area in fluid communication with an incubation area and a waste area.
  • In fluid communication with the main channel is at least one side reagent channel.
  • the side reagent channels comprise, in a direction of fluid flow, a liquid addition port and a side reagent area in fluid communication with the main channel at a region of the main channel upstream from the incubation area.
  • Agitation means may be included in at least one of the main and side reagent areas and/or the incubation area.
  • Capillary valves may be located at various positions along the main and side reagent channels upstream from the incubation area, providing for control over fluid flow through the device. The complicated mechanical nature of this device renders it unsuitable for repeated, accurate, use.
  • a nonbibulous lateral flow one-step assay for an analyte in biological sample using a lateral flow strip discloses a design for a nonbibulous lateral flow one-step assay for an analyte in biological sample using a lateral flow strip.
  • three zones that are in nonbibulous lateral flow contact are employed: a sample receiving zone, a labeling zone, and a capture zone.
  • the sample containing analyte is carried through the labeling zone and interacts with an assay label comprising a visible moiety, preferably particles, which are coupled to a specific binding reagent for an analyte or to a competitor with analyte for a capture reagent.
  • Control label comprising visible moieties (preferably, visually distinguishable from those of the assay label) may also be included in the labeling zone and captured in a separate control portion of the capture zone to verify that the flow of liquid is as expected.
  • the control label does not correct for the variability between lateral flow strips, leading to inaccurate and inconsistent measurements.
  • proof of movement of the control label across the control portion of the capture zone provide proof of movement of the assay label moiety across the analyte specific portion of the capture zone.
  • Eisinger, et al, U. S. Patent Number 4,943,522 discloses a method and apparatus for conducting specific binding pair assays, such as immunoassays.
  • a porous membrane capable of non-bibulous lateral flow is used as an assay substrate; a member of the binding pair is affixed in an indicator zone defined in the substrate.
  • the sample is applied at a position distant from the indicator zone and permitted to flow laterally through the zone; any analyte in the sample is completed by the affixed specific binding member, and detected.
  • this assay does not have any controls, which can lead to testing inaccuracies and errors.
  • Campbell, et al, U. S. Patent Number 4,703,017 discloses a solid-phase assay for an analyte wherein binder is supported on a solid support, such as nitrocellulose, and the tracer comprises ligand labeled with a colored particulate label, such as a liposome, including a dye.
  • the assay has high sensitivity, and the tracer is visible on the support under assay conditions, whereby tracers is disclosed as determined, without instrumentation, and without further treatment thereof.
  • human subjectivity is introduced into the assay, leading to inaccuracy and error.
  • Patent Number 4,743,560 discloses a solid-phase assay for an analyte wherein binders are supported on a solid support, such as nitrocellulose, and the tracer is comprised of ligand labeled with a particulate label, such as a liposome, including a detectable marker which is not visible.
  • this assay does not have any controls, which can lead to testing inaccuracies and errors.
  • Brooks, U.S. Patent No. 5,753,517 discloses methods of measuring the amount of an analyte of interest in a fluid sample, using a quantitative immunochromatographic assay, and an apparatus for use in the assay.
  • the assay utilizes a rapid antigen measurement platform (RAMP®) apparatus.
  • the apparatus includes a membrane strip made of a material such as cellulose nitrate or glass fiber that has sufficient porosity and the ability to be wet by the fluid containing the analyte, and allows movement of particles by capillary action.
  • the membrane strip is disclosed as having an application point, a contact region, and a detection zone; the contact region is between the application point and the detection zone.
  • Imbedded in the contact region is a population of particles, such as colloidal metal particles, organic molecules, liposomes, or organic polymer latex particles.
  • the particles are coated with an antibody to the analyte of interest.
  • the particles can be labeled, using a colorimetric, fluorescent, luminescent, or other appropriate label, to facilitate detection.
  • a detection reagent is immobilized in the detection zone.
  • the detection reagent can be an antibody to the analyte of interest, or can be the analyte of interest itself.
  • the apparatus can also include one or more of the following features: an application pad that rests on and covers the application point; a contact pad that rests on and covers the contact region, and which may have antibody-coated particles imbedded within it. If a contact pad is present, a separator pad is disclosed as present and resting on the membrane in between the contact region and the contact pad. Also disclosed are a wicking pad that may rest on the membrane adjacent to the detection zone, such that the detection zone is between the wicking pad and the contact region; and an internal control that includes internal control particles imbedded in the contact region, a control detection reagent, and a control reaction zone.
  • the apparatus includes an internal control for the disclosed purpose of compensating for variations in membrane properties from assay to assay.
  • the internal control includes internal control particles, a control detection reagent, and a control reaction zone. Internal control particles are disclosed as imbedded in the contact region with the antibody-coated particles.
  • the "internal control particles” are similar to the antibody-coated particles. They are disclosed as coated with the same surface concentration of an antibody, except that the antibody on the internal control particles is directed against a control detection reagent that does not react with the antibody directed against the analyte.
  • the "control detection reagent” is disclosed as a reagent that does not interact with either the analyte to be measured, the antibody on the antibody-coated particles, or the detection reagent.
  • the control detection reagent is coated on the membrane on the "control reaction zone".
  • the control reaction zone refers to a point on the membrane strip at which the control detection reagent is immobilized.
  • control agents therefore function poorly in methods designed to compensate for assay variability by measuring the relative response to control and analyte detection agents in each lateral flow device.
  • the invention relates to a method of performing a lateral flow assay comprising contacting an analyte of interest with a first analyte binding agent, wherein the first analyte binding agent and an analyte nonspecific agent are coupled to a detection agent.
  • the invention in another aspect, relates to a method, in a lateral flow assay that comprises a test strip, of increasing the difference between an average positive result of the assay and an average negative result of the assay comprising spatially relocating on the test strip one or more control binding zones with respect to an analyte binding zone.
  • the invention relates to a method, in a lateral flow assay that comprises a test strip, of reducing the coefficient of variability of the lateral flow assay comprising spatially relocating on the test strip one or more control binding zones with respect to an analyte binding zone.
  • the invention relates to a method, in a lateral flow assay, of increasing the reproducibility of the lateral flow assay comprising quantifying a first amount of detection agent present in a first control zone; quantifying a second amount of detection agent present in a second control zone; mapping the quantified first and second amounts of detection agent onto a relative scale to arrive at relative first and second amounts of detection agent; and wherein the mapping is performed such that the ratio of the quantified first amount of detection agent to the quantified second amount of detection agent is greater than the ratio of the relative first amount of detection agent to the relative second amount of detection agent.
  • the invention relates to a lateral flow assay comprising a test strip comprising an analyte binding agent and an analyte non-specific agent coupled to a detection agent.
  • FIG. 1 shows a cross-section of an embodiment of a lateral flow test strip according to the invention.
  • analyte refers to the molecule or compound to be quantitatively determined.
  • examples of analytes include proteins, such as hormones and other secreted proteins, enzymes, and cell surface proteins; glycoproteins; peptides; small molecules; polysaccharides; antibodies (including monoclonal or polyclonal Ab and portions thereof); nucleic acids; drugs; toxins; viruses or virus particles; portions of a cell wall; and other compounds possessing epitopes.
  • the analyte of interest preferably comprises an immunogenic portion, meaning that antibodies (as described below) can be raised to that portion of the analyte of interest.
  • Test strip 100 includes backing strip 102, membrane strip 104, separation pad 106, conjugate pad 108, test zone 110, low control zone 112, high control zone 114, absorbent pad 116, and protective covering 118.
  • Test strip 100 comprises a distal and proximal end. Examples of suitable test strip arrangements include those available from Scripps Laboratories as the Scripps Laboratories Lateral-Flow Immunoassay Development System.
  • Mounted centrally on backing strip 102 is membrane strip 104. Located distally from membrane strip 104, with a slight overlap with membrane strip 104, is conjugate pad 108.
  • separation pad 106 Located distally on backing strip 102 from conjugate pad 108, in a nearly fully overlapping manner, is separation pad 106. Additionally located on backing strip 102 is absorbent pad 116, which is in contact with and proximal from membrane strip 104. Protective covering 118 is coupled to separation pad 106, membrane strip 104, and absorbent pad 116 in an opposing relationship to backing strip 102.
  • Backing strip 102 may be made of a stable, non-porous material that is sufficiently strong to support the materials and strips coupled to it. Generally, backing strip 102 is substantially impervious to water. In a preferred embodiment, backing strip 102 is made of a polymer film, more preferably a poly( vinyl chloride) film.
  • Test strip 100 also comprises absorbent pad 116.
  • the absorbent pad comprises an absorbent substance that may soak up solution that has been transported by capillary action to the end of membrane strip 104.
  • Examples of substances suitable for use in absorbent pad 116 include cellulose and glass fiber.
  • Protective covering 118 is coupled to membrane strip 104 in an opposing relationship to backing strip 102.
  • Protective covering 118 protects or covers membrane strip 104, conjugate pad 108, absorbent pad 116 and optionally separation pad 106
  • Protective covering 118 may be made of a material generally impervious to water, and is preferably translucent or transparent.
  • Protective covering 118 may be a single or multiple layers.
  • Preferable materials for use in protective covering 118 comprise optically transmissive materials such as polyamide, polyester, polyethylene, acrylic, glass, or similar materials.
  • the protective covering 118 may be clear or not clear depending on method of detection used. In a preferable embodiment, protective covering 118 is optically clear polyester.
  • Membrane strip 104 may be made of a substance having the following characteristics: sufficient porosity to allow capillary action of fluid along its surface and through its interior; the ability to allow movement of antibody- or antigen-coated particles by capillary action (i.e., it preferably does not block the particles); and the ability to be wet by the fluid containing the analyte (e.g., hydrophilicity for aqueous fluids, hydrophobicity for organic solvents). Hydrophobicity of a membrane can be altered to render the membrane hydrophilic for use with aqueous fluid, by processes such as those described in U.S. Pat. No. 4,340,482, or U.S. Pat. No.
  • membrane substances include: cellulose, nitrocellulose, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and polyethersulfone.
  • the membrane strip is made of nitrocellulose.
  • Separation pad 106 may be made of an absorbent substance that can deliver a fluid sample, when applied to separation pad 106, to conjugate pad 108.
  • Preferred substances include, but are not limited to, cellulose, nitrocellulose, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and polyethersulfone.
  • Conjugate pad 108 is coupled to separation pad 106.
  • Conjugate pad 108 may be made of an absorbent substance; representative substances include cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and polyethersulfone.
  • the conjugate pad may contain a population of first analyte binding agent and analyte non-specific agent coupled to a detection agent. In alternative embodiments, this population may be present elsewhere in the test strip, either exclusively or non-exclusively.
  • Analyte non-specific agent is defined as an agent non-specific to the analyte of interest.
  • the first analyte binding agents are agents that specifically bind to the analyte of interest. More than one population of first analyte binding agent and analyte non-specific agent coupled to a detection agent may be present in the test strip. These populations may be the same or different in composition, location or other characteristics.
  • the first analyte binding agents are antibodies to the analyte of interest.
  • the analyte of interest is an antibody of known specificity
  • the population may comprise the antigen against which the analyte-antibody is directed.
  • the antibodies can be monoclonal antibodies or polyclonal antibodies.
  • antibody also refers to antibody fragments that are sufficient to bind to the analyte of interest.
  • molecules that specifically bind to the analyte of interest such as engineered proteins, peptides, haptens, and lysates containing heterogeneous mixture of antigens having analyte binding sites, may also be used.
  • the analyte of interest is a ligand
  • a receptor which binds to the ligand can be used, and vice versa.
  • the first analyte binding agent and analyte non-specific agent are coupled to a detection agent.
  • the detection agent may comprise a wide variety of materials, so long as it facilitates detection of the first analyte binding agent to which the detection agent is coupled.
  • Suitable detection agents comprise particles, luminescent labels; colorimetric labels, fluorescent labels; chemical labels; enzymes; radioactive labels; or radio frequency labels; metal colloids; and chemiluminescent labels.
  • At least one first analyte agent and at least one analyte nonspecific agent are coupled to a single detection agent.
  • a single detection agent comprises a single population of detection agent moieties coupled to at least one first analyte agent and at least one analyte nonspecific agent.
  • This embodiment may serve to reduce non-specific binding and may correct for certain types of assay variability.
  • Different detection agents may be used if different populations of first analyte binding agent and analyte non-specific agent coupled to a detection agent are used. This situation may arise, for example, when it is desired to assay two different analytes of interest on the same test strip.
  • Use of two different detection agents facilitates detection of the two different analytes of interest.
  • the detection agent is a fluorescent agent
  • the detection agents may be selected to fluoresce at different wavelengths.
  • the detection agent is a particle.
  • particles useful in the practice of the invention include, but are not limited to, colloidal gold particles; colloidal sulphur particles; colloidal selenium particles; colloidal barium sulfate particles; colloidal iron sulfate particles; metal iodate particles; silver halide particles; silica particles; colloidal metal (hydrous) oxide particles; colloidal metal sulfide particles; colloidal lead selenide particles; colloidal cadmium selenide particles; colloidal metal phosphate particles; colloidal metal ferrite particles; any of the above-mentioned colloidal particles coated with organic or inorganic layers; protein or peptide molecules; liposomes; or organic polymer latex particles, such as polystyrene latex beads.
  • JO- Preferable particles are colloidal gold particles.
  • the size of the particles may be related to porosity of the membrane strip: the particles are preferably sufficiently small to be transported along the membrane by capillary action of fluid.
  • Colloidal gold may be made by any conventional means, such as the methods outlined in G. Frens, 1973 Nature Physical Science, 241:20 (1973). Alternative methods may be described in U.S. Patent Nos. 5,578,577, 5,141,850; 4,775,636; 4,853,335; 4,859,612; 5,079,172; 5,202,267; 5,514,602; 5,616,467; 5,681,775.
  • the selection of particle size may influence such factors as stability of bulk sol reagent and its conjugates, efficiency and completeness of release of particles from conjugate pad 108 , speed and completeness of the reaction. Also, particle surface area may influence stearic hindrance between bound moieties.
  • the particles may be labeled to facilitate detection. Examples of labels include, but are not limited to, luminescent labels; colorimetric labels, such as dyes; fluorescent labels; or chemical labels, such as electroactive agents (e.g., ferrocyanide); enzymes; radioactive labels; or radio frequency labels.
  • the number of particles present in the test strip may vary, depending on the size and composition of the particles, the composition of the test strip and membrane strip , and the level of sensitivity of the assay.
  • the number of particles typically ranges between about 1X10 9 and about 1X10 13 particles, although fewer than about 1X10 9 particles may be used. In a preferred embodiment, the number of particles is about 1X10 11 particles.
  • a analyte non-specific agent is also coupled to the detection agent. This analyte non-specific agent may be selected for its ability to bind to substances other than the analyte of interest. For example, if the analyte of interest is an antibody to H.
  • the analyte non-specific agent may be an antibody to an antigen not found, or rarely found, in the antibody to H. Pylori. This binding may be specific for a substance other than the analyte of interest or non-specific for such a substance.
  • the analyte non-specific agent may be antibodies, more preferably rabbit IgG.
  • the antibodies can be monoclonal antibodies or polyclonal antibodies.
  • the term "antibody”, as used herein, also refers to antibody fragments that are sufficient to bind to the analyte of interest.
  • molecules such as engineered proteins having binding sites non-specific for the analyte of interest, may also be used.
  • a receptor that specifically binds to ligands other than the analyte of interest can be used, and vice versa.
  • analyte non-specific agent may be an antigen, another organic molecule, or a hapten conjugated to a protein non-specific for the analyte of interest.
  • suitable analyte non-specific agents may be found in U.S. Patent No. 5,096,837, and include IgG, other immunoglobulins, bovine serum albumin (BSA), other albumins, casein, and globulin.
  • the analyte non-specific agent comprises a control binding agent.
  • Control binding agents are selected so as to bind specifically to molecules other than molecules that specifically bind to the analyte of interest. In this way, these control binding agents can bind to control zones, as discussed below.
  • Substances useful as control binding agents include those substances described above as useful as first analyte binding agents.
  • the control binding agent comprises rabbit anti- dinitrophenol (anti-DNP) antibody. Additional beneficial characteristics of control binding agents include, but are not limited to stability in bulk, non- specificity for analyte of interest, reproducibility and predictability of performance in test, molecular size, and avidity of binding to the control agent.
  • the coupling of the first analyte binding agent and the analyte nonspecific agent to the detection agent may be covalent or non-covalent (e.g., ionic, hydrogen bonding, Van der Waals forces, etc.). Conventional coupling chemistries and techniques are suitable for use in this invention. Further, each of the first analyte binding agent, the detection agent and the analyte nonspecific agent may be coupled to one another, through one another, or through linker, carrier or spacer groups.
  • both first analyte binding agent and analyte non-specific agent may be coupled by nonspecific adsorption to the detection agent.
  • traditional conjugate chemistry may be used to covalently couple both the first analyte binding agent and the analyte non-specific agent to the particle.
  • a non-covalent binding system such as biotin-avidin, or even a second antibody specific for the first analyte binding agent to be detected, may be used to couple a detection agent such as a fluorescent label to the first analyte binding agent, and the analyte non-specific agent may be directly coupled to the first analyte binding agent.
  • bifunctional or multifunctional reagents may be used to couple the first analyte binding agent, the detection agent and the analyte non-specific agent.
  • the number of first analyte binding agents and analyte non-specific agents coupled to the detection agent may vary as appropriate to the particular embodiment. For example, two first analyte binding agents may be coupled to one detection agent and one analyte nonspecific agent. Alternatively, two analyte non-specific agents may be coupled to one detection agent and one first analyte binding agent. Other variations on these arrangements will no doubt occur to one of skill in the art, and as such are encompassed within the scope of the invention.
  • Each detection zone is located such that an automatic or semi-automatic analytical instrument, or a human reader, may determine certain results of the lateral flow assay.
  • the detection zone comprises a measurement zone, in which measurements of certain results of the lateral flow assay may be performed.
  • the detection zone may comprise one or more analyte binding zones and/or one or more control binding zones.
  • Analyte binding zones are areas of the membrane strip that comprise a second analyte binding agent.
  • One or more of the substances discussed above as suitable first analyte binding agents may be used as second analyte binding agents in the analyte binding zone.
  • the first analyte binding agent is an antigen recognized by the analyte of interest, which is an antibody.
  • the second analyte binding agent may also be the antigen or even a second antibody specific for the analyte (antibody) of interest.
  • the analyte of interest is an antigen.
  • the second analyte binding agent, which is an antibody may be directed against a different epitope of the analyte compared to the first analyte binding agent, when the latter is also an antibody.
  • the analyte is an antigen with multiple copies of the same epitope
  • the second analyte binding agent may be directed against the same epitope as the first analyte binding agent.
  • one or more measurement zones may also comprise at least one control binding zone.
  • a control binding zone comprises at least one control agent.
  • a control agent binds specifically to the control binding agent to form a control binding pair.
  • control binding pairs according to the invention are internal controls ⁇ that is, the control against which the analyte measurement results may be compared is present on the individual test strip. Therefore, the controls according to the invention may be used to correct for strip-to-strip variability. Such correction would be impractical with external controls that are based, for example, on a statistical sampling of strips. Additionally, lot-to-lot and run-to-run, variations between different test strips may be minimized by use of control binding agents and control agents according to the invention. Furthermore, the effects of non-specific binding, as discussed further below, may be reduced. All of these corrections would be difficult to accomplish using external, off-strip controls.
  • the inventive lateral flow device may possess more than one control binding zone on the test strip.
  • the control binding zones may be made to create a calibration curve against which a wide variety of analyte measurement results-may be compared.
  • possessing more than one internal control may permit making of lateral flow assays possessing a wider dynamic range than conventional lateral flow assays.
  • multiple control binding zone test strips are used with a relative scale methodology, discussed further below, that permits mapping of amounts of control binding pairs detected onto the same scale on which amounts of analyte detected are reported.
  • inventive assays will have at least one high control binding zone and at least one low control binding zone.
  • the difference between the two zones is generally one of concentration.
  • the concentration of control agent in the high control binding zone is greater than the concentration of control agent in the low control binding zone.
  • the amount of control binding pairs will be higher in the high control zone versus the low control zone.
  • a calibration curve may be drawn through the values of the binding pairs in the high and low control binding zones.
  • control binding zones may be present. This allows for a curve to be generated that better reflects any nonlinearities present in the assay between the amount of analyte detected and the measurement against which the amount might be mapped, as discussed below. While such nonlinearities might otherwise affect assays that assume a relatively linear relationship, they can be corrected for using multiple control binding zones.
  • a single control binding zone may comprise more than one type of control agent. This may be of use in embodiments where there are more than one population of analyte binding agents and analyte nonspecific agents coupled to a detection agent. For example, when it is desired to assay two or more analytes of interest on the same assay strip, two populations of analyte binding agents and analyte non-specific agents coupled to a detection agent may be prepared. Different detection agents may be used for each population, allowing a distinction to be drawn between results for the two different analytes of interest. In such circumstances, it may be desirable to use control binding zones comprising different control agents or control binding pairs.
  • control agents comprise those substances listed above that are suitable for use as control binding agents, save that the control agents bind specifically to the control binding agents.
  • the control binding agent is rabbit anti-DNP IgG
  • the control agent is DNP conjugated to BSA (bovine serum albumin).
  • control binding zones may be located in a variety of locations within the measurement zone that comprises it, and measurement zones comprising control binding zones may located in a variety of locations on the test strip. Rearrangement of control binding zones relative to analyte binding zones and reservoir(s) of the population of first analyte binding agent, analyte non-specific agent, and detection agent may be desirable in differing assays. For example, when the reservoir containing the population is located in the conjugate pad, it may be desirable in certain embodiments to locate the analyte binding zone(s) between the conjugate pad and the control binding zone(s). In other embodiments, it may be desirable to locate the control binding zone(s) between the analyte binding zone(s) and the conjugate pad.
  • control binding zones and analyte binding zones on the strip may affect the absolute binding of the analyte binding agent to the detection zone and the control binding agent to the control detection zone. This effect may result in an increase or decrease of the ratio of the control to detection analyte measurements, especially in cases where very strong positive specimens are tested. Such changes may have an impact on assay cutoff, if one is used; on assay precision at the cutoff; or on overall assay dynamic range and reproducibility.
  • performing the inventive lateral flow assay may begin by obtaining a fluid sample containing the analyte of interest.
  • the fluid can be a fluid that wets membrane strip 104; that supports an antibody/antigen reaction
  • the fluid is an aqueous solution (such as a bodily fluid).
  • separation pad 106 is contacted with the fluid sample containing the analyte of interest. After separation pad 106 is contacted with the fluid sample containing the analyte of interest, test strip 100 is maintained under conditions that allow fluid to transport the analyte of interest by capillary action to conjugate pad 108.
  • analyte of interest present in the fluid contacts the first analyte binding agent coupled to the detection agent, of which conjugate pad 108 is comprised. At this point, contact also occurs between substances contained in the fluid and the analyte non-specific agent coupled to the detection agent. Both specific binding and non-specific binding may occur as a result of these contacts, to form a variety of complexes. It is preferable that all or nearly all of the specific binding take place between the analyte of interest and the first analyte binding agent.
  • Capillary action of the fluid from the fluid sample mobilizes the first analyte binding agent (coupled to the detection agent and the analyte non-specific agent), bound or unbound, moving it laterally to membrane strip 104. Additionally, complexes comprising non-specifically bound detection agent might form and grow in size, particularly if the various agents involved bind non-specifically to other components present in the sample. Capillary action may also mobilize such complexes, even if they are very large.
  • protective covering 118 minimizes loss of fluid through evaporation and resulting evaporative cooling, resulting in improved consistency and reproducibility, although it is not required to practice the invention. Retaining proper fluid volume is important for completeness of fluid flow along test strip 100. Prevention of evaporative cooling is useful for speed and completeness of the assay reactions. Additionally, protective covering 118 functions to keep infectious agents self-contained within the test strip 100.
  • the movement of the first analyte binding agent, together with other complexes, may be arrested as it reaches a measurement zone within a detection zone. If the measurement zone includes second analyte binding agent specific for the analyte of interest or the control binding agent, then the first analyte binding agent and/or the control binding agent, and anything coupled or complexed to them, directly or indirectly, may be immobilized at the measurement zone. Once the first analyte binding agent and/or the control binding agent, and anything coupled or complexed to them, directly or indirectly, are immobilized at the measurement zone, their presence may be detected using the detection agent. The amount of detection agent arrested in the measurement zone may be quantified using conventional techniques.
  • optical methods such as measuring light scattering, simple reflectance, luminometer or photomultiplier tube; radioactivity (measured with a Geiger counter, etc.); electrical conductivity or dielectric (capacitance); electrochemical detection of released electroactive agents, such as indium, bismuth, gallium or tellurium ions, as described by Hayes et al. (Analytical Chem. 66:1860-1865 (1994)) or ferrocyanide as suggested by Roberts and Durst (Analytical Chem. 67:482-491
  • the amount may then be mapped onto another measurement scale.
  • the result of the inventive assay may be measured as a density of reflectance (Dr)
  • the result reported may be more meaningful in other units, such as RI (intensity relative to that of a control zone or control zones).
  • Results may also be expressed as the number of copies of analyte present in the measurement volume.
  • the mapping of the amount of analyte detected onto other measurement scales is a preferable embodiment for reporting results of the inventive assay. For instance, the assay results may be mapped onto a relative scale.
  • RI Relative Intensity
  • Dr Density of Reflectance
  • a low control may be assigned an RI value of 1 and a high control may be assigned an RI value of 3, even though the ratio of the absolute Dr values of these controls may be different.
  • the absolute Dr ratio may be at least about 5:1, while the RI ratio may be about 3:1.
  • the inventive assays may be used in a "cut-off style assay. If the detection agent is detected in an analyte binding zone, the amount of detection agent detected may be compared against a cut-off value.
  • a cut-off value is the value above which the test may be considered positive; that is, the analyte of interest is present in the fluid sample to some degree of statistical confidence. Below the cut-off value, the test is generally considered not positive ⁇ either the analyte of interest is not present or the inventive lateral flow assay did not detect its presence. While a cut-off may established based upon a directly measured value, such as the amount of analyte detected, the results may be more meaningful if reported on an indirect, or relative, scale.
  • a cut-off lateral flow assay is more desirable as the measurement separation between a negative value and a positive value increases.
  • a negative value is the reported value on the continuous scale in the case where the analyte of interest is statistically not present.
  • a positive value is the reported value on the continuous scale in the case where the analyte of interest is statistically present. As these values converge, the likelihood reduces of being able to statistically tell positives and negatives apart.
  • inventive assay results may be mapped onto either a "relative,” discussed above, or an "absolute" scale.
  • Absolute scales are measured in actual physical units, such as number of copies of analyte per milliliter of fluid. Measurement in the absolute scale may be preferable in testing for certain diseases or conditions, such as tests for cancer markers. In such preferable embodiments, the result may be expressed in units, such as ng/ml. Accordingly, the control zones may have value assigned concentrations of control agent.
  • the density of reflectance (DR) values of a series of standards of known analyte concentration may be measured and the intensities relative to the controls (RI values) calculated as previously described.
  • the RI values may then be plotted against analyte concentration to construct a standard curve in which the RI values are assigned concentration values of the analyte of interest.
  • the RI of a sample may then be read on this value assigned standard curve, yielding a result labeled in the desired units.
  • the single population of analyte binding agents and analyte non-specific agents coupled to detection agent according to the invention offers advantages over two population assays.
  • Two population assays may comprise, in one embodiment, one population of analyte binding agents coupled to detection agents, and another population of analyte non-specific agents coupled to detection agents.
  • single population lateral flow assays may be made according to the invention that demonstrate advantages versus similar two population lateral flow assays. These advantages include being able to practice the assay in such a way as to provide a wider measurement separation of negative and positive sample populations, together with increased precision at the cut-off.
  • lateral flow assays Many circumstances may affect the absolute reactivity of lateral flow assays, including, but not limited to, manufacturing-derived variations, operator induced variations, environmentally induced variations and sample effects. With conventional lateral flow assays, any of these variations may act to repress or arguably enhance reactivity of one strip over another, resulting in possible false negative or false positive results. Not controlling for these or other variations may result in significant imprecision, non-reproducibility, lack of sensitivity and lack of specificity of the tests.
  • Lateral flow assays are also subject to a number of interferences which might affect the absolute amount of binding of either analyte binding agent or analyte non-specific agent to the control binding zone or the analyte binding zone.
  • Influencing factors may include: 1) variability in the release of the analyte binding agent or the control binding agent from a conjugate pad, 2) device to device variation in the non-specific binding of the analyte binding population to the test strip, 3) variability in the movement of the analyte binding population through or along the test strip during the assay due to variation in the pore size of the test strip or membrane strip materials or non-specific aggregation of the analyte binding agent. Variability of absolute measurements of binding due to these or other factors may therefore be unacceptably high in conventional lateral flow assays.
  • control binding agent and detection agent provide several advantages over conventional lateral flow assays with a population comprising control binding agents and another, separate, population comprising analyte binding agents.
  • any portion of the lateral flow assay matrix that has been exposed to the analyte non-specific agent is more likely to have been exposed to the analyte detection agent, as compared to conventional two-population assays.
  • any mechanism that impedes or prevents movement of the analyte non-specific agent along or through the lateral flow matrix is more likely to impede or prevent movement of the analyte detection agent, as compared to conventional two-population assays.
  • the analyte non-specific agent may be chosen so as to reduce the amount of non-specific binding of the analyte detection agent. Furthermore, reduction of non-specific binding may occur due to modification of hydrophobicity/hydrophilicity profile of the analyte detection matrix.
  • Reduction in aggregation "self-association" of the analyte detection matrix particles, which might hinder movement of matrix along the strip, may also be achieved by choosing an analyte non-specific agent with suitable properties.
  • a final advantage is that, due to the need to prepare fewer reagents, manufacturing costs may be reduced.
  • Multiple control zones offer a number of potential advantages in the practice of lateral flow assays. Additional control zones may be used to extend the dynamic range of the assay standard curve whether the curve is linear or nonlinear. Multiple control zones may also be used to define whether a prozone or high dose hook effect is present in a given assay. If such an effect is present, then the user can be advised to dilute the sample to unambiguously determine the concentration of the analyte in question
  • the lateral flow assays according to the invention may find use in a variety of applications.
  • the inventive assays may be used to assay for human diseases, such as infectious diseases, or any other human diseases involving recognizable epitopes (e.g. cancer, autoimmune disease, cardiovascular conditions and pathology).
  • the inventive assays may also be used in veterinary, food testing, agricultural, or fine chemical applications.
  • the lateral flow assays according to the invention may be performed in variety of ways, including use of a lateral flow assay testing apparatus, such as that disclosed in the co-pending patent application of Polito et al., entitled “Method and Apparatus for Performing a Lateral Flow Assay," filed on , with an Application Serial No. (Atty. Docket No. 19669-702), hereby incorporated by reference.
  • the lateral flow assay testing apparatus comprises a ReLIATM testing apparatus, available from
  • a Helicobacter pylori single population conjugate was prepared as follows: Six hundred milliliters of 16 nm gold sol (Frens, G., Nature (London) Phys. Sci. 241:20 (1973)) were adjusted to pH 9.5 with 100 mM Potassium carbonate. The solution was placed in a polypropylene beaker on a stirring motor. A mixture was then prepared of rabbit anti-DNP and Helicobacter pylori extract, containing amounts of each reagent equal to twice that necessary to completely block aggregation of the gold sol by sodium chloride (Geoghegan, W.D. et al., J. Histochem. Cytochem. 25:1187 (1977) ).
  • Bovine Serum Albumin in deionized water was added and stirring was continued for an additional thirty minutes at room temperature.
  • the colloidal gold conjugate was then placed in 250 ml centrifuge bottles and spun down at room temperature for 30 minutes at 13000 RPM (27000 XG) in the GSA head of a Sorvall RC-5C centrifuge. At the end of this time, the supematants were removed by aspiration and the colloidal gold conjugate was dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was then diluted to approximately 600 ml with 10 mM sodium borate pH 9.0 containing 0.1% PEG (MW 20,000) (Borate/PEG) and again centrifuged as above. Upon completion of the centrifugation, the supematants were removed by aspiration and the colloidal gold conjugate was again dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was again diluted to approximately 600 ml with Borate/PEG and centrifuged a final time as above. Upon completion of the centrifugation, the conjugate was dispersed in the remaining liquid by vortex mixing and sonication and then diluted to approximately 15 ml with Borate/PEG. The conjugate solution was then 0.2 micron filtered and stored at 4° C. The yield was 15 ml of material with an optical density of 26.64 at 520 nm.
  • An HIV single population conjugate was prepared as follows: Three hundred milliliters of 16 nm gold sol (Frens, G., Nature (London) Phys. Sci. 241:20 (1973)) were adjusted to pH 9.5 with 100 mM Potassium carbonate. The solution was placed in a polypropylene beaker on a stirring motor. A mixture was then prepared of rabbit anti-DNP and HIV envelope antigen env- 131 -Horseradish peroxidase conjugate containing amounts of each reagent equal to twice that necessary to completely block aggregation of the gold sol by sodium chloride (Geoghegan, W.D. et al., J. Histochem. Cytochem. 25:1187 (1977) ).
  • the mixture (4.5 ml) was added to the gold sol with stirring at room temperature and adsorption of the proteins to the gold sol was carried out for ten minutes. At the end of this time, 6 ml of a 0.2 micron filtered solution of Bovine Serum Albumin in deionized water was added and stirring was continued for an additional thirty minutes at room temperature.
  • the colloidal gold conjugate was then placed in 250 ml centrifuge bottles and spun down at room temperature for 60 minutes at 13000 RPM (27000 XG) in the GSA head of a Sorvall RC-5C centrifuge. At the end of this time, the supematants were removed by aspiration and the colloidal gold conjugate was dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was then diluted to approximately 300 ml with 10 mM sodium borate pH 9.0 containing 0.1 % PEG (MW 20,000) (Borate/PEG) and again centrifuged as above. Upon completion of the centrifugation, the supematants were removed by aspiration and the colloidal gold conjugate was again dispersed in the remaining liquid by vortex mixing and sonication. The colloidal gold conjugate was again diluted to approximately 300 ml with 10 mM sodium borate pH 9.0 containing 0.1% PEG (MW 20,000) (Borate/PEG) and centrifuged a final time as above. Upon completion of the centrifugation, the conjugate was dispersed in the remaining liquid by vortex mixing and sonication and then diluted to approximately 10 ml with Borate/PEG. The conjugate solution was then 0.2 micron filtered and stored at
  • the yield was 9.5 ml of material with an optical density of 26.74 at 520 nm.
  • a control conjugate was prepared as follows: Twelve hundred milliliters of 41 nm gold sol (Frens, G., Nature (London) Phys. Sci. 241:20 (1973)) were adjusted to pH 9.5 with 100 mM Potassium carbonate. The solution was placed in a polypropylene beaker on a stirring motor. A solution was then prepared of rabbit anti-DNP containing reagent equal to twice that necessary to completely block aggregation of the gold sol by sodium chloride (Geoghegan, W.D. et al., J. Histochem. Cytochem. 25:1187 (1977) ).
  • the solution (12 ml) was added to the gold sol with stirring at room temperature and adsorption of the proteins to the gold sol was carried out for ten minutes. At the end of this time, 24 ml of a 0.2 micron filtered solution of Bovine Serum Albumin in deionized water was added and stirring was continued for an additional thirty minutes at room temperature.
  • the colloidal gold conjugate was then placed in 250 ml centrifuge bottles and spun down at room temperature for 30 minutes at 13000 RPM (27000 XG) in the GSA head of a Sorvall RC-5C centrifuge. At the end of this time, the supematants were removed by aspiration and the colloidal gold conjugate was dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was then diluted to approximately 1200 ml with 10 mM sodium borate pH 9.0 containing 0.1 % PEG (MW 20,000)
  • the yield was 42 ml of material with an optical density of 11.76 at 520 nm.
  • a Helicobacter pylori conjugate was prepared as follows: One hundred forty milliliters of 16 nm gold sol (Frens, G., Nature (London) Phys. Sci. 241:20 (1973)) were adjusted to pH 9.5 with 100 mM Potassium carbonate. The solution was placed in a polypropylene beaker on a stirring motor. A solution was then prepared of Helicobacter pylori extract containing reagent equal to twice that necessary to completely block aggregation of the gold sol by sodium chloride and nonspecific rabbit IgG equal to twice that necessary to completely block sodium chloride induced aggregation of the gold sol. Geoghegan, W.D. et al., J. Histochem. Cytochem.
  • the solution (2.8 ml) was added to the gold sol with stirring at room temperature and adsorption of the proteins to the gold sold was carried out for ten minutes. At the end of this time, 2.8 ml of a 0.2 micron filtered solution of Bovine Serum Albumin in deionized water was added and stirring was continued for an additional thirty minutes at room temperature.
  • the colloidal gold conjugate was then placed in 250 ml centrifuge bottles and spun down at room temperature for 30 minutes at 13000 RPM (27000 XG) in the GSA head of a Sorvall RC-5C centrifuge. At the end of this time, the supematants were removed by aspiration and the colloidal gold conjugate was dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was then diluted to approximately 140 ml with 10 mM sodium borate pH 9.0 containing 0.1% PEG (MW 20,000) (Borate/PEG) and again centrifuged as above. Upon completion of the centrifugation, the supematants were removed by aspiration and the colloidal gold conjugate was again dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was again diluted to approximately 140 ml with Borate/PEG and centrifuged a final time as above. Upon completion of the centrifugation, the conjugate was dispersed in the remaining liquid by vortex mixing and sonication and then diluted to approximately 5 ml with
  • the yield was 4.5 ml of material with an optical density of 28.4 at 520 nm.
  • HIV detection conjugate was prepared as follows: Four hundred milliliters of 16 nm gold sol (Frens, G., Nature (London) Phys. Sci. 241:20 (1973)) were adjusted to pH 9.5 with 100 mM Potassium carbonate. The solution was placed in a polypropylene beaker on a stirring motor. A solution was then prepared of HIV envelope antigen env-131 -Horseradish peroxidase conjugate containing reagent equal to twice that necessary to completely block aggregation of the gold sol by sodium chloride and nonspecific rabbit IgG containing twice that necessary to completely block sodium chloride induced aggregation of the gold sol (Geoghegan, W.D. et al., J. Histochem. Cytochem. 25:1187 (1977) ).
  • Bovine Serum Albumin in deionized water was added and stirring was continued for an additional thirty minutes at room temperature.
  • the colloidal gold conjugate was then placed in 250 ml centrifuge bottles and spun down at room temperature for 30 minutes at 13000 RPM (27000 XG) in the GSA head of a Sorvall RC-5C centrifuge. At the end of this time, the supematants were removed by aspiration and the colloidal gold conjugate was dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was then diluted to approximately 400 ml with 10 mM sodium borate pH 9.0 containing 0.1% PEG (MW 20,000) (Borate/PEG) and again centrifuged as above. Upon completion of the centrifugation, the supematants were removed by aspiration and the colloidal gold conjugate was again dispersed in the remaining liquid by vortex mixing and sonication.
  • the colloidal gold conjugate was again diluted to approximately 400 ml with Borate/PEG and centrifuged a final time as above. Upon completion of the centrifugation, the conjugate was dispersed in the remaining liquid by vortex mixing and sonication and then diluted to approximately 15 ml with Borate/PEG. The conjugate solution was then 0.2 micron filtered and stored at 4° C. The yield was 12 ml of material with an optical density of 26.66 at 520 nm.
  • Test strips were manufactured according to the following procedure. Backed sheets of Millipore STHF nitrocellulose 2.5 cm X 20 cm were coated by longitudinally dispensing one antigen and two control bands onto the nitrocellulose using a Bio Dot XYZ3000 dispensing platform with Biojets operating at a frequency of 120 Hz, 20.83 nl/drop, and 0.5 ul/cm.
  • the control antigen was Dinitrophenylated Bovine Serum Albumin (DNP-BSA) in Phosphate buffered saline (PBS) containing 0.05% Tween 20.
  • DNP-BSA Dinitrophenylated Bovine Serum Albumin
  • PBS Phosphate buffered saline
  • High control was coated in the range of 150 - 500 ug/ml and low control was coated in the range of 15 - 100 ug/ml as appropriate to the individual assay.
  • Antigens were coated in the range of 0.5 - 4 mg/ml, as appropriate to the individual assay, in phosphate buffered saline containing detergent.
  • Reducing agent such as DTT and/or ethylenediamine tetraacetic acid (EDTA) were added to the antigen solution if active sulfhydryl groups were present.
  • HIV env-131 antigen was coated at 2 mg/ml in PBS, 2 mM EDTA, 10 mM DTT, 0.2% sodium dodecyl sulfate (SDS), high control coating concentration was 300 ug/ml and low control coating concentration was 25 ug/ml.
  • SDS sodium dodecyl sulfate
  • Sheets were then dried for one hour at 37 °C for one hour in a forced air incubator, blocked for fifteen minutes in a solution of PBS containing 10 mg/ml BSA, 1% (w/v) PEG 8000, 3% (w/v) mannitol, 0.3% (w/v) gelatin, 0.01% (w/v) sodium azide and 0.05% (w/v) sodium dodecyl sulfate, and then dried for an additional hour in a forced air incubator at 37 °C.
  • Coated sheets were stored desiccated at room temperature in foil pouches.
  • Gelman 8980 glass fiber pads were preblocked by dipping in a solution of PBS 10 mg/ml BSA, 2 mg/ml rabbit IgG, 1% (w/v) Triton X-100, 2.5% (w/v) sucrose and 0.3% (w/v) polyvinylpyrrolidone K-30 and then drying for 1.5 hours in a forced air incubator.
  • the preblocked conjugate pads were coated with either HIV OMNITM conjugate, made according to Example 2, or Helicobacter pylori OMNITM conjugate, made according to Example 1, by mixing equal volumes of the stock conjugate solution (OD 520 approximately 26) with PBS 20 mg/ml BSA, 4 mg/ml rabbit IgG, 2% (w/v) Triton X-100, 5%
  • Test strips were prepared by affixing one 2.5 cm X 20 cm backed nitrocellulose sheet, one 1.8 cm X 20 cm sheet of Gelman Type 133 Absorbent Pad, two 1 cm X 10 cm conjugate coated pads (side by side) and one 2 cm X 20 cm Gelman Cytosep 1662 sheet to one adhesive coated .010" thick 6 cm X 20 cm vinyl backing sheet (G&L Precision Die Cutting) in the configuration shown in FIG. 1. Clear adhesive backed polyester film (G&L Precision Die Cutting) was used to cover the test strip from the top 2 mm of the cytosep to the top of the absorbent pad. Strips 0.5 cm wide were cut from the assembled sheet with a Bio Dot Cutter 3000TM.
  • Strips used in this example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control zone and the high control zone farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0J85 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Example 8 Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0.185 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • the assay was earned out by placing the cassette containing the strip in a ReLIATM machine set up to run and read the H pylori assay.
  • Strip temperature was set to 37 °C Strips were read after 15 minutes.
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was analyte binding (i.e. antigen) zone closest to the conjugate pad, low control zone between the analyte binding (i.e. antigen) zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, 1.0.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS. The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Strips used in this example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control zone and the high control zone farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml
  • Example 12 Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Example 13 Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0.185 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6. The assay was carried out by placing the cassette containing the strip in a ReLIATM machine set up to run and read the H pylori assay.
  • Strip temperature was set to 37 °C Strips were read after 15 minutes.
  • Example 14 Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was analyte binding (i.e. antigen) zone closest to the conjugate pad, low control zone between the analyte binding (i.e. antigen) zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Example 15 Strips used in this example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control zone and the high control zone farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0.185 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Example 16 Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1%) sodium azide and 2 mM EDTA.
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0.185 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1% sodium azide and 2 mM EDTA.
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was analyte binding (i.e. antigen) zone closest to the conjugate pad, low control zone between the analyte binding (i.e. antigen) zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, 1.0.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0J%o sodium azide and 2 mM EDTA.
  • Strips used in this example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control zone and the high control zone farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0.185 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • the assay was carried out by placing the cassette containing the strip in a ReLIATM machine set up to run and read the H. pylori assay. At the prompt, the assay was commenced by adding a 25 ul sample (as indicated below) followed by 3 drops of wash buffer (PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0J%> sodium azide and 2 mM EDTA). Strip temperature was set to 37 °C Strips were read after 15 minutes.
  • wash buffer PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0J%> sodium azide and 2 mM EDTA.
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • the assay was carried out by placing the cassette containing the strip in a ReLIATM machine set up to run and read the H. pylori assay. At the prompt, the assay was commenced by adding a 25 ul sample (as described below) followed by 3 drops of wash buffer (PBS, 0.05% Triton X-100, 0.5% PEG
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was low control zone closest to the conjugate pad, analyte binding (i.e. antigen) zone between the low control zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 0.968 ml of the conjugate described in Example 3, 0.681 ml of the conjugate described in Example 4, 1.868 ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG, 0.094 ml 20X PBS and 0J85 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • Strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a solution of Helicobacter pylori extract having an optical density at 280 nm of 2.70 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was analyte binding (i.e. antigen) zone closest to the conjugate pad, low control zone between the analyte binding (i.e. antigen) zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • Conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 1, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • the assay was canied out by placing the cassette containing the strip in a ReLIATM machine set up to ran and read the H. pylori assay. At the prompt, the assay was commenced by adding a 25 ul sample (as described below) followed by 3 drops of wash buffer (PBS, 0.05% Triton X-100, 0.5% PEG (20K), O.P/o sodium azide and 2 mM EDTA). Strip temperature was set to 37 °C Strips were read after 15 minutes. The results were as follows:
  • Format 1 separate conjugate populations of particles having control binding agent and particles having analyte binding agent, with the analyte binding zone placed between a high control zone and a low control zone;
  • Format 2 separate conjugate populations of particles having control binding agent and particles having analyte binding agent, with the high control zone and low control zone placed after the analyte binding zone place and the conjugate pad;
  • Format 3 OMNITM conjugate populations of particles comprising control binding agent and analyte binding agent, with the analyte binding zone placed between a high control zone and a low control zone; and Format 4: OMNITM conjugate populations of particles comprising control binding agent and analyte binding agent, with the high control zone and low control zone placed after the analyte binding zone place and the conjugate pad
  • Format 2 produces the lowest coefficients of variation on the HC/LC ratio and the lowest readings for H. pylori- ⁇ QgdXivQ samples.
  • Format 3 produces the highest readings for H v/ort-positive samples.
  • Format 4 produces the best precision at the designated cut-off value, and also has the greatest spread between measured values for H j ⁇ y/or/-negative samples and H >v/or/-positive samples.
  • Format 2 and format 4 strips used in this Example were coated with 300 ug/ml Dinitrophenyl conjugated bovine serum albumin (BSA-DNP) in the high control zone, 25 ug/ml BSA-DNP in the low control zone and a 2 mg/ml solution of HIV envelope antigen env-131 in the analyte binding (i.e. antigen) zone.
  • the order of the bands on the strip was analyte binding (i.e. antigen) zone closest to the conjugate pad, low control zone between the analyte binding (i.e. antigen) zone and the high control and the high control farthest from the conjugate pad and closest to the absorbent pad.
  • Nitrocellulose sheets were coated and strips prepared as described in Example 6.
  • conjugate pads were preblocked in OJM sodium phosphate pH 7.4 containing 0.5 M sodium chloride, 1% (w/v) casein, 1 mM EDTA, 1% (w/v) Triton X-100, 0.1% (w/v) sodium azide, 0.05% (w/v) Gentamycin sulfate, 0.1% (w/v) yeast extract, 0.05% (w/v) E. coli extract, 1%> (w/v) BSA, 0.3% polyvinylpyrrolidone, 0.05 % SDS, 2.5% sucrose and 2 mg/ml rabbit IgG and dried for 1.5 hours at 37 °C.
  • Conjugate mixture was prepared by mixing 0.908 ml of the conjugate described in Example 3, 1.440 ml of the conjugate mixture described in Example 5 and 1.388 ml of 10 mM Borate pH 9.0, 0.1% PEG (MW 20000). The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • conjugate pads were prepared by mixing 1.0 ml of the conjugate described in Example 2, l.O.ml of PBS 20 mg/ml BSA, 2% Triton X-100, 5% sucrose, 0.6% PVP K-30 and 4 mg/ml rabbit IgG and 0.050 ml 20X PBS. The mixture was dispensed onto preblocked conjugate pads as described in Example 6.
  • the assays were carried out by placing the cassette containing the strip in a ReLIATM machine set up to run and read the HIV assay. At the prompt, the assay was commenced by adding a 25 ul sample (either HIV+ or HIV-) followed by 3 drops of wash buffer (PBS, 0.05% Triton X-100, 0.5% PEG (20K), 0.1%) sodium azide and 2 mM EDTA). Strip temperature was set to 37
  • control zones and the ability to express results as intensity relative to the control bands helps to improve assay reproducibility and precision at the cutoff. This may be accomplished in the inventive single population embodiment by improved control of sources of assay variability compared to separate populations of first analyte detection and control detection particles.
  • inventive single population embodiment by improved control of sources of assay variability compared to separate populations of first analyte detection and control detection particles.
  • present invention encompasses embodiments that may possess multiple (two or more) populations of first analyte binding agents and analytes non-specific agents coupled to detection agents.
  • control binding zones and analyte binding zones on the strip appeared to affect assay performance in the above Examples. Moving from the conjugate pad to the absorbent pad, the optimum assay configuration appeared to be analyte binding (i.e. antigen) zone, low control zone and high control zone for both the

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des essais en écoulement latéral (papier réactif) caractérisés par: une ou plusieurs zones de contrôle possédant un agent de contrôle (dinitrophénol par exemple) immobilisé dans ces dernières; un agent de détection consistant en une conjugaison de liant d'analyte (extrait d'helicobacter pylori ou antigène d'enveloppe HIV par exemple), de liant de contrôle (anticorps dirigé contre le dinitrophénol) et d'un marqueur (or colloïdal 16 nm, permettant les mesures de réflectance).
PCT/US1999/027497 1998-11-23 1999-11-18 Essais en ecoulement lateral ameliores Ceased WO2000031538A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17390/00A AU1739000A (en) 1998-11-23 1999-11-18 Improved lateral flow assays

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19811898A 1998-11-23 1998-11-23
US09/198,118 1998-11-23
US09/442,383 1999-11-17

Publications (1)

Publication Number Publication Date
WO2000031538A1 true WO2000031538A1 (fr) 2000-06-02

Family

ID=22732055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027497 Ceased WO2000031538A1 (fr) 1998-11-23 1999-11-18 Essais en ecoulement lateral ameliores

Country Status (2)

Country Link
CN (1) CN1254844A (fr)
WO (1) WO2000031538A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048771A3 (fr) * 2001-12-04 2003-11-27 Lattec I S Dispositif permettant d'analyser des analytes et utilisation correspondante
EP1143248A3 (fr) * 2000-02-29 2004-02-11 Boehringer Mannheim Gmbh Méthode pour l'immobilisation de conjugates dans des épreuves diagnostiques
EP1416275A1 (fr) * 2002-10-31 2004-05-06 Oy Reagena Ltd Procédé de test rapide et dispositiv de contrôle
EP1507148A1 (fr) * 2003-08-25 2005-02-16 MTM Laboratories AG Procédé de détection de carcinomes dans des échantillons corporels cervicaux solubilisés
WO2005111607A2 (fr) 2004-05-12 2005-11-24 Roche Diagnostics Gmbh Procede pour elargir la plage de mesure dynamique d'elements servant a realiser des tests notamment immunologiques, bases sur des reactions de fixation specifiques
WO2006003394A1 (fr) * 2004-07-01 2006-01-12 Central Science Laboratory (Csl) Representing The Secretary Of State For Environment, Food And Rural Affairs Systeme de detection d'analytes
WO2006036247A1 (fr) * 2004-09-28 2006-04-06 Kimberly-Clark Worldwide, Inc. Detection d'infections a levures par dosage a ecoulement lateral
US7041787B2 (en) 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
EP1808696A1 (fr) * 2006-01-14 2007-07-18 Roche Diagnostics GmbH Elément de test immunologique doté d'une zone de contrôle améliorée
US20090180928A1 (en) * 2005-04-22 2009-07-16 Alverix, Inc. Assay test strips with multiple labels and reading same
GB2475630A (en) * 2006-03-11 2011-05-25 Central Science Lab Representing The Sec Dep For Environment Food And Rural Affairs Two-stage detection assay
US8043811B2 (en) 2006-03-11 2011-10-25 The Food & Environment Research Agency (FERA) representing the Secretary of State for Environment, Food and Rural Affairs Purification method and kits
WO2013040435A3 (fr) * 2011-09-16 2013-05-23 Credo Biomedical Pte Ltd Dispositif de dosage de diagnostic moléculaire et procédé d'utilisation
EP2271939B1 (fr) * 2008-04-09 2015-06-17 Becton Dickinson and Company Immuno-essais sensibles utilisant des nanoparticules revêtues
CN106841602A (zh) * 2017-01-21 2017-06-13 上海源紊新能源科技有限公司 一种邻苯二甲酸二丙烯酯胶体金免疫层析检测试纸
CN107907679A (zh) * 2017-11-06 2018-04-13 南京诺唯赞医疗科技有限公司 一种免疫层析试纸条及其制作方法与应用
US9989527B2 (en) 2004-04-01 2018-06-05 Alverix, Inc. Lateral flow assay systems and methods
JP2020020724A (ja) * 2018-08-02 2020-02-06 積水メディカル株式会社 イムノクロマト用試験片及びイムノクロマト検出キット
CN111157721A (zh) * 2020-01-15 2020-05-15 珠海丽珠试剂股份有限公司 用于提高肺炎衣原体抗原/支原体抗原在免疫层析试剂中稳定性的包被液及其制备方法
CN111413506A (zh) * 2018-01-30 2020-07-14 深圳市伯劳特生物制品有限公司 一种检测试纸条在制备检测pla2r抗体的试剂盒中的应用
CN111413501A (zh) * 2018-01-30 2020-07-14 深圳市伯劳特生物制品有限公司 一种检测试纸条在制备检测thsd7a抗体的试剂盒中的应用
CN114594251A (zh) * 2022-03-10 2022-06-07 上海艾瑞德生物科技有限公司 一种il-6荧光免疫层析试剂盒及其制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105814A2 (fr) 2006-08-22 2008-09-04 Los Alamos National Security, Llc Dispositif à écoulement latéral miniaturisé pour détection rapide et sensible de protéines ou d'acides nucléiques
US8980561B1 (en) 2006-08-22 2015-03-17 Los Alamos National Security, Llc. Nucleic acid detection system and method for detecting influenza
EP3067694A1 (fr) 2008-05-05 2016-09-14 Los Alamos National Security, LLC Préparation d'échantillons d'acide nucléique à base de flux latéral et régulation d'écoulement de fluide passif
KR101027036B1 (ko) * 2009-05-28 2011-04-11 주식회사 인포피아 금 이온의 환원에 의한 측방유동 분석에서의 신호 증폭 방법 및 이를 이용한 측방유동 분석 디바이스
KR101508670B1 (ko) 2011-04-20 2015-04-07 메사 테크 인터내셔널, 인코포레이티드 핵산 검출 및 동정을 위한 통합 장치
CN102879571A (zh) * 2012-09-25 2013-01-16 中华人民共和国淮安出入境检验检疫局 一种快速检测铜离子的胶体金增敏层析试纸条
CN104251908B (zh) * 2013-06-28 2016-03-30 广州万孚生物技术股份有限公司 样品垫处理液、h7亚型禽流感病毒胶体金试纸条及其制备方法
SG10202005427PA (en) 2015-04-24 2020-07-29 Mesa Biotech Inc Fluidic test cassette
CN105092567B (zh) * 2015-07-15 2019-01-29 宁波高新区绿邦科技发展有限公司 盐酸克伦特罗-莱克多巴胺-沙丁胺醇三联检测试剂卡
CN105203723A (zh) * 2015-07-15 2015-12-30 宁波高新区绿邦科技发展有限公司 快速定量检测盐酸克伦特罗的检测装置及其检测方法
CN105044366A (zh) * 2015-07-15 2015-11-11 宁波高新区绿邦科技发展有限公司 新型盐酸克伦特罗检测试剂卡
JP6741013B2 (ja) * 2015-10-16 2020-08-19 東洋紡株式会社 イムノクロマト試験片
CN107037211B (zh) * 2016-11-04 2019-03-01 苏州海苗生物科技有限公司 一种定量检测化合物的测试条及侧向免疫层析的检测方法
CN112946253B (zh) * 2019-12-11 2022-11-08 广东菲鹏生物有限公司 用于免疫诊断试剂中固相载体的封闭阶段处理剂及应用和产品
CN112362864B (zh) * 2021-01-12 2021-04-30 广州科方生物技术股份有限公司 一种降低免疫诊断试剂背景发光值的处理剂及其制备方法
CN116930513B (zh) * 2023-09-19 2023-11-17 北京索莱宝科技有限公司 一种用于蛋白检测的无蛋白快速封闭液及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009620A1 (fr) * 1995-09-07 1997-03-13 Agen Biomedical Limited Procede et appareil destines a l'evaluation quantitative et semi-quantitative d'une substance a analyser
US5661019A (en) * 1987-09-30 1997-08-26 Beckman Instruments, Inc. Trifunctional conjugates
EP0833157A1 (fr) * 1996-09-27 1998-04-01 Unilever Plc Réactifs et dispositifs d'analyse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661019A (en) * 1987-09-30 1997-08-26 Beckman Instruments, Inc. Trifunctional conjugates
WO1997009620A1 (fr) * 1995-09-07 1997-03-13 Agen Biomedical Limited Procede et appareil destines a l'evaluation quantitative et semi-quantitative d'une substance a analyser
EP0833157A1 (fr) * 1996-09-27 1998-04-01 Unilever Plc Réactifs et dispositifs d'analyse

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241418B2 (en) 2000-02-29 2007-07-10 Roche Diagnostics Corporation Method for immobilizing conjugates in diagnostic tests
EP1143248A3 (fr) * 2000-02-29 2004-02-11 Boehringer Mannheim Gmbh Méthode pour l'immobilisation de conjugates dans des épreuves diagnostiques
US6998246B2 (en) 2000-02-29 2006-02-14 Roche Diagnostics Corporation Method for immobilizing conjugates in diagnostic tests
US7241628B2 (en) 2000-02-29 2007-07-10 Roche Diagnostics Corporation Method for immobilizing conjugates in diagnostic tests
US7041787B2 (en) 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
WO2003048771A3 (fr) * 2001-12-04 2003-11-27 Lattec I S Dispositif permettant d'analyser des analytes et utilisation correspondante
EP1416275A1 (fr) * 2002-10-31 2004-05-06 Oy Reagena Ltd Procédé de test rapide et dispositiv de contrôle
EP1507148A1 (fr) * 2003-08-25 2005-02-16 MTM Laboratories AG Procédé de détection de carcinomes dans des échantillons corporels cervicaux solubilisés
WO2005088311A1 (fr) * 2003-08-25 2005-09-22 Mtm Laboratories Ag Methode de detection des troubles neoplasiques a partir d'un echantillon corporel solubilise
US7932047B2 (en) 2003-08-25 2011-04-26 Mtm Laboratories, Ag Method for detecting neoplastic disorders in a solubilized body sample
US9989527B2 (en) 2004-04-01 2018-06-05 Alverix, Inc. Lateral flow assay systems and methods
US8354235B2 (en) 2004-05-12 2013-01-15 Roche Diagnostics Operations, Inc. Method for increasing the dynamic measuring range of test elements based on specific binding reactions
WO2005111607A2 (fr) 2004-05-12 2005-11-24 Roche Diagnostics Gmbh Procede pour elargir la plage de mesure dynamique d'elements servant a realiser des tests notamment immunologiques, bases sur des reactions de fixation specifiques
US7763433B2 (en) 2004-07-01 2010-07-27 Forsite Diagnostics Limited Analyte detection system
GB2433989B (en) * 2004-07-01 2009-04-08 Central Science Lab Analyte detection system
GB2433989A (en) * 2004-07-01 2007-07-11 Central Science Lab Analyte delection system
AU2005259012B2 (en) * 2004-07-01 2011-01-20 Forsite Diagnostics Limited Analyte detection system
WO2006003394A1 (fr) * 2004-07-01 2006-01-12 Central Science Laboratory (Csl) Representing The Secretary Of State For Environment, Food And Rural Affairs Systeme de detection d'analytes
WO2006036247A1 (fr) * 2004-09-28 2006-04-06 Kimberly-Clark Worldwide, Inc. Detection d'infections a levures par dosage a ecoulement lateral
US11782058B2 (en) 2005-04-22 2023-10-10 Alverix, Inc. Diagnostic test system using measurement obtained from reference feature to modify operational parameter of reader
US10753931B2 (en) 2005-04-22 2020-08-25 Alverix, Inc. Assay test strips with multiple labels and reading same
US10191043B2 (en) 2005-04-22 2019-01-29 Alverix, Inc. Methods and systems for calibrating illumination source of diagnostic test system
US10041941B2 (en) * 2005-04-22 2018-08-07 Alverix, Inc. Assay test strips with multiple labels and reading same
US20090180928A1 (en) * 2005-04-22 2009-07-16 Alverix, Inc. Assay test strips with multiple labels and reading same
US9891217B2 (en) 2005-04-22 2018-02-13 Alverix, Inc. Assay test strips with multiple labels and reading same
US9528986B2 (en) 2006-01-14 2016-12-27 Roche Diagnostics Operations, Inc. Immunological test element with control zone for identifying hook effect
US10429382B2 (en) 2006-01-14 2019-10-01 Roche Diagnostics Operations, Inc. Immunological test element with control zone for identifying hook effect
US8951806B2 (en) 2006-01-14 2015-02-10 Roche Diagnostics Operations, Inc. Immunological test element with improved control zone
EP1808696A1 (fr) * 2006-01-14 2007-07-18 Roche Diagnostics GmbH Elément de test immunologique doté d'une zone de contrôle améliorée
US8043811B2 (en) 2006-03-11 2011-10-25 The Food & Environment Research Agency (FERA) representing the Secretary of State for Environment, Food and Rural Affairs Purification method and kits
GB2475630A (en) * 2006-03-11 2011-05-25 Central Science Lab Representing The Sec Dep For Environment Food And Rural Affairs Two-stage detection assay
EP2952897A1 (fr) * 2008-04-09 2015-12-09 Becton, Dickinson and Company Immunoessais sensibles à l'aide de nanoparticules revêtues
EP2271939B1 (fr) * 2008-04-09 2015-06-17 Becton Dickinson and Company Immuno-essais sensibles utilisant des nanoparticules revêtues
US10598656B2 (en) 2011-09-16 2020-03-24 Credo Biomedical Pte Ltd. Method of selecting analyte to samples using a lateral flow device
WO2013040435A3 (fr) * 2011-09-16 2013-05-23 Credo Biomedical Pte Ltd Dispositif de dosage de diagnostic moléculaire et procédé d'utilisation
CN106841602A (zh) * 2017-01-21 2017-06-13 上海源紊新能源科技有限公司 一种邻苯二甲酸二丙烯酯胶体金免疫层析检测试纸
CN107907679A (zh) * 2017-11-06 2018-04-13 南京诺唯赞医疗科技有限公司 一种免疫层析试纸条及其制作方法与应用
CN111413506A (zh) * 2018-01-30 2020-07-14 深圳市伯劳特生物制品有限公司 一种检测试纸条在制备检测pla2r抗体的试剂盒中的应用
CN111413501A (zh) * 2018-01-30 2020-07-14 深圳市伯劳特生物制品有限公司 一种检测试纸条在制备检测thsd7a抗体的试剂盒中的应用
JP2020020724A (ja) * 2018-08-02 2020-02-06 積水メディカル株式会社 イムノクロマト用試験片及びイムノクロマト検出キット
CN111157721A (zh) * 2020-01-15 2020-05-15 珠海丽珠试剂股份有限公司 用于提高肺炎衣原体抗原/支原体抗原在免疫层析试剂中稳定性的包被液及其制备方法
CN111157721B (zh) * 2020-01-15 2022-12-09 珠海丽珠试剂股份有限公司 用于提高肺炎衣原体抗原/支原体抗原在免疫层析试剂中稳定性的包被液及其制备方法
CN114594251A (zh) * 2022-03-10 2022-06-07 上海艾瑞德生物科技有限公司 一种il-6荧光免疫层析试剂盒及其制备方法

Also Published As

Publication number Publication date
CN1254844A (zh) 2000-05-31

Similar Documents

Publication Publication Date Title
WO2000031538A1 (fr) Essais en ecoulement lateral ameliores
US6528323B1 (en) Bidirectional lateral flow test strip and method
US7309611B2 (en) Prewetting stop flow test strip
US7238538B2 (en) Chromatographic assay device and methods
JP3358737B2 (ja) 改良された投与量応答曲線を有するアッセイ
EP0299428B1 (fr) Procédé pour l'immunochromatographie avec des particules colloidales
AU619480B2 (en) Lateral flow chromatographic binding assay device
EP0988546B1 (fr) Dispositif analytique pour tests a base de membranes
US7344893B2 (en) Immuno-gold lateral flow assay
EP0480497B1 (fr) Appareil pour l'exécution d'un dosage à la main unique et rapide
JP2012524277A (ja) 試験ストリップのダイナミックレンジの拡張
WO1994002850A1 (fr) Dispositifs transparents pour analyses, et procedes associes
US8101429B2 (en) Native analyte as a reference in lateral flow assays
WO1999064863A1 (fr) Essais colorimetriques colloidaux en ecoulement continu et en ecoulement lateral utilisant des particules submicroniques solubles
JP2001228151A (ja) 免疫クロマトグラフィー装置
CA2198948A1 (fr) Detection quantitative des composantes d'un melange dans les bandes immunochromatographiques
HK1024743B (en) Analytical device for membrane-based assays

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17390

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase